ArticleBMC cancer2026
C21orf2 as a potential regulator of JAK2/STAT3 signaling in prostate cancer cell proliferation and apoptosis: an exploratory study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is a major health concern for men worldwide, and its incidence is rising rapidly, so identifying key molecules that regulate the malignant biological behavior of PCa is crucial for early diagnosis and targeted therapy. This study aimed to elucidate the regulatory role of chromosome 21 open reading frame 2 (C21orf2) in the biological functions of prostate cancer cells and further explore the molecular mechanisms by which C21orf2 regulates cell proliferation and apoptosis via the JAK2/STAT3 signaling pathway. MATERIALS AND
methodsIn vitro, C21orf2’s effects on cell proliferation, migration, invasion, and apoptosis were tested using CCK-8, scratch assays, Transwell assays, TUNEL staining, and electron microscopy. Western blotting assessed the impact of C21orf2 on JAK2/STAT3 proteins and related markers. Co-immunoprecipitation and immunofluorescence explored interactions with downstream targets. In vivo, a subcutaneous xenograft model in nude mice validated C21orf2’s role in tumor growth and apoptosis.
resultsC21orf2 was upregulated in prostate cancer tissues and regulated the malignant biological behavior of prostate cancer cells, and C21orf2 showed a negative correlation with KCTD5. High expression of C21orf2 promoted the activation of the JAK2/STAT3 signaling pathway and upregulated its downstream target genes, including c-MYC, Cyclin A1, Bcl-2, and Cleaved caspase-3, thereby promoting cell proliferation and inhibiting apoptosis.
conclusionsOur study indicates that C21orf2 is a potential biomarker for the diagnosis and treatment of prostate cancer and highlights its potential as a therapeutic target through the JAK2/STAT3 signaling pathway in prostate cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.